Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report

We previously published in the Journal of Thoracic Oncology the case of a patient with EGFR and MET-driven lung cancer and extracranial response to capmatinib and osimertinib. Here, we report on a second patient treated with the same combination, revealing complete and durable intracranial response....

Descripción completa

Detalles Bibliográficos
Autores principales: Gautschi, Oliver, Diebold, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474278/
https://www.ncbi.nlm.nih.gov/pubmed/34590012
http://dx.doi.org/10.1016/j.jtocrr.2021.100162
_version_ 1784575176453652480
author Gautschi, Oliver
Diebold, Joachim
author_facet Gautschi, Oliver
Diebold, Joachim
author_sort Gautschi, Oliver
collection PubMed
description We previously published in the Journal of Thoracic Oncology the case of a patient with EGFR and MET-driven lung cancer and extracranial response to capmatinib and osimertinib. Here, we report on a second patient treated with the same combination, revealing complete and durable intracranial response. Adding capmatinib to osimertinib seems to be an effective salvage therapy for patients with EGFR-mutant lung cancer and acquired MET amplification.
format Online
Article
Text
id pubmed-8474278
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84742782021-09-28 Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report Gautschi, Oliver Diebold, Joachim JTO Clin Res Rep Case Report We previously published in the Journal of Thoracic Oncology the case of a patient with EGFR and MET-driven lung cancer and extracranial response to capmatinib and osimertinib. Here, we report on a second patient treated with the same combination, revealing complete and durable intracranial response. Adding capmatinib to osimertinib seems to be an effective salvage therapy for patients with EGFR-mutant lung cancer and acquired MET amplification. Elsevier 2021-03-09 /pmc/articles/PMC8474278/ /pubmed/34590012 http://dx.doi.org/10.1016/j.jtocrr.2021.100162 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Gautschi, Oliver
Diebold, Joachim
Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report
title Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report
title_full Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report
title_fullStr Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report
title_full_unstemmed Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report
title_short Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report
title_sort intracranial activity of osimertinib plus capmatinib in a patient with egfr and met-driven lung cancer: case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474278/
https://www.ncbi.nlm.nih.gov/pubmed/34590012
http://dx.doi.org/10.1016/j.jtocrr.2021.100162
work_keys_str_mv AT gautschioliver intracranialactivityofosimertinibpluscapmatinibinapatientwithegfrandmetdrivenlungcancercasereport
AT dieboldjoachim intracranialactivityofosimertinibpluscapmatinibinapatientwithegfrandmetdrivenlungcancercasereport

Ejemplares similares